secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089566
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma Q2 2023: cash $87.6M, NDA for etripamil due Oct 2023
---------------------------------------------------------------------

- Cash, equivalents & short-term investments of $87.6M; runway into mid-2025.
- NDA submission for etripamil nasal spray (PSVT) planned for October 2023.
- Enrollment complete in Phase 2 ReVeRA trial (AFib-RVR); topline data Q4 2023.
- Operating loss Q2 2023: $16.4M vs $16.8M in Q2 2022; R&D expense down to $8.6M.
- Commercial expense rose to $3.4M in Q2 2023 from $2.2M a year earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/tm2323072d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer